Jump to content
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Legal Disclaimer

    All use of the Rosacea Research & Development Institute (RRDi or irosacea.org) Web site is subject to the terms and conditions set forth below. When referring to the Rosacea Research & Development Institute (RRDi or irosacea.org) in this legal discaimer includes the following domains:


    Any use of such Web pages constitutes the user's agreement to abide by the following terms and conditions.

    The Rosacea Research & Development Institute [RRDi] is a non profit corporation registered in the states of Alabama and Hawaii, USA as well as recognized June 7, 2004 by the USA Internal Revenue Service as a 501 (c) (3) non profit tax exempt organization.

    All medical information on this Web site has been reviewed for accuracy. However, the information posted here by the Rosacea Research & Development Institute or any third party should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The Institute does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case.

    Links to other Web sites found on irosacea.org are provided as a service to our users. Such linkage does not constitute endorsement of the site by the Rosacea Research & Development Institute, and the Institute is not responsible for the content of external web sites. Links to commercial rosacea web sites are prohibited at this time.

    The Rosacea Research & Development Institute Web pages are designed for educational purposes only. This information is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified health care provider. The Rosacea Research & Development Institute does not endorse or attest to the validity or accuracy of any treatments or medications discussed herein. Before acting on any information contained on the Web pages, you agree that you will consult your health care provider to determine whether the information you are relying on is appropriate for your medical condition.

    All information provided by the Rosacea Research & Development Institute is owned by or licensed to the Rosacea Research & Development Institute. The Rosacea Research & Development Institute retains all proprietary rights to the information contained on the pages. Except for making one hard copy print of the information or downloading the material for a one-time use, information on the pages may not be reproduced, transmitted, distributed, or displayed, without the express consent of the Rosacea Research & Development Institute.



    The RRDi does not knowlingly use any material (images or text) that is copyrighted by others. If you believe any materials accessible on or from this web site infringe your copyright, you may request removal of those materials (or access thereto) from this web site by the RRDi copyright agent (identified below) and providing the following information:
    Identification of the copyrighted work that you believe to be infringed. Please describe the work, and where possible include a copy or the location (e.g., URL) of an authorized version of the work. Identification of the material that you believe to be infringing and its location. Please describe the material, and provide us with its URL or any other pertinent information that will allow us to locate the material. Your name, address, telephone number and (if available) e-mail address.
    A statement that you have a good faith belief that the complained of use of the materials is not authorized by the copyright owner, its agent, or the law.
    A statement that the information that you have supplied is accurate, and indicating that "under penalty of perjury," you are the copyright owner or are authorized to act on the copyright owners behalf.

    A signature or the electronic equivalent from the copyright holder or authorized representative.

    The irosacea.org agent for copyright issues relating to this web site is as follows:

    RRDi Copyright Agent
    PO Box 858
    Centre, Alabama, 35960

    Or use our contact form explaining your copyright issue with our website. We will handle such matters in an appropriate and timely manner. 

    In an effort to protect the rights of copyright owners, the irosacea.org maintains a policy for the termination, in appropriate circumstances, of subscribers and account holders of this web site who are repeat infringers.

    International Disclaimer

    This Web site can be accessed from other countries around the world and may contain references to rosacea products, services, treatments or programs that have not been announced in your country. These references do not imply that irosacea.org intends to announce such products, services or programs in your country.

    Governing Law and Jurisdiction

    This web site (excluding linked sites) is controlled by irosacea.org from its office within the state of Hawaii, United States of America. By accessing this Web site, you and irosacea.org agree that all matters relating to your access to, or use of, this Web site shall be governed by the statutes and laws of the state of Hawaii, without regard to the conflicts of laws principles thereof. You and irosacea.org also agree and hereby submit to the exclusive personal jurisdiction and venue of the Superior Court of the District of Honolulu, Honolulu County and the United States District Court for the District of Hawaii with respect to such matters. irosacea.org makes no representation that materials on this Web site are appropriate or available for use in other locations, and accessing them from territories where their contents are illegal is prohibited. Those who choose to access this site from other locations do so on their own initiative and are responsible for compliance with local laws.

    Privacy Policy

    Our Privacy Policy is the commitment to respect the privacy of the information entrusted to our institute with your personal information by not giving your personal information to others or using it inappropriately. If you have any questions or concerns regarding our privacy policy please direct them to privacy@irosacea.org

    You may also send a letter to:

    Rosacea Research & Development Institute, PO Box 858, Centre, Alabama 35960

    irosacea.org does not sell, exchange, or release your personal information (name, e-mail address, mailing address, credit card data, etc.) without your consent to any third parties.

    Information gathered through the use of cookies is not related to any personally identifiable details.

    What information does irosacea.org collect from our users and how do we collect it?

    irosacea.org only contacts individuals who specifically request that we do so. irosacea.org collects personally identifying information from our users during (1) online registration, (2) online public surveys, (3) online purchasing, and (4) messages posted to our public forum board and the private forum. Generally, this information includes name, e-mail address, postal address, and answers to public survey questions. This information is used for internal purposes and helps us determine how to continually improve our site and the institute. Names and email addresses may be posted in public forums and public databases by individual members who post such information on their own. The RRDi is not responsible if a member posts their own real name, address, phone number, or email address. If a member later regrets posting this information the member can report where the post is and have it removed upon request. If you do not want your name listed in any of the public surveys or databases you should use a bogus name or alias (nickname) since the institute is not responsible if you use your real name or email address in a public survey or database. However, the institute will not publicly display any of the members names, email addresses or postal addresses. Each member is responsible for his or her own privacy when using any of the institute's web site when posting. Non voting members can join the RRDi by providing an email address. 

    Members who donate to the RRDi are named in public financial records unless the donor specifically instructs us that the donation is anonymous.

    Corporate Members Forum Guidelines and Privacy Policy

    The corporate members only private forum is provided as a free service of the RRDi. The institute will not release any names, mailing addresses or email addresses of who is using the private (or public) forum to any third parties without your consent.

    Privacy is important to the RRDi and you can rest assured your contact information is safe with us and we will not disclose your contact info to anyone without your permission or only if we are required by law to disclose your contact info. The privacy policy also includes the Member Forum, Blog and Gallery areas of our site as well as the Tapatalk hosted private form. The Guidelines policy is enforced and binding on all members and guests.

    Blog, Clubs and Gallery

    The Blog, Clubs and Gallery, if available, are provided as a free service by the RRDi to its members only and you are responsible for your own privacy with regard to this service if you engage with another member and disclose your private information in the Blog, Clubs or post photos in the Gallery. The RRDi cannot be held responsible for your privacy if you use the Blog, Clubs or Gallery and our privacy policy, legal disclaimer, rules, and official documents are still binding if you violate this policy.  We warn you to not disclose your private information or post inappropriate content in the Blog, Clubs or Gallery.

    The institute will not release any names or email addresses of who is using the Blog, Clubs or Gallery service without your consent.


    What are cookies and how do we use them?

    Cookies help track a person''s session while online. They are used on our site to gather basic tracking information. Cookies are not related to any personally identifiable information and are not used to retrieve information from your computer that was not originally sent in a cookie.

    Many browsers are set to accept cookies. You may prefer to set your browser to refuse cookies. It is possible, however, that some areas of the site will not function properly if you do so. This is especially likely when trying to order a publication.

    Third-Party Advertising

    Advertisements are not currently allowed on this site. If advertisements are allowed then information about your visits to this site, such as the number of times you have viewed an ad (but not your name, address, or other personal information), is used to serve ads to you. In the course of serving advertisements to this site, third-party advertisers may place or recognize unique cookies on your browser. Links to third-party advertising, or commercial web sites are prohibited.

    Amazon Affiliate

    The RRDi has joined Amazon Affiliates and links to items at amazon.com may be placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.

    Demodex Solutions Affiliate

    The RRDi has joined the Demodex Solutions affiliate program and links to this program are placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.


    This policy may be changed at any time at Rosacea Research & Development Institute's discretion.


    © Rosacea Research & Development Institute. All rights reserved. Reproduction, re-transmission or reprinting of the contents of this Web site, in part or in its entirety, is expressly prohibited without prior written permission from the Rosacea Research & Development Institute.

  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
    Richard Trafford-Owen
  • Posts

    • Rosacea of the scalp: Results from a retrospective and prospective randomized controlled study
    • Just an update on the RRDi. As the end of 2023 was getting closer, there simply wasn't enough donations to keep our website going, not to mention other costs to keep a legal 501 C 3 non profit going. There hasn't been any activity in our member forum for some time now, many months. i was resigned to close up the RRDi since members don't post, only a few donate a few dollars a month. Then in October 2023 one of our members, David Peterson, donated $1000 which kept us going for another year. You can view our financial situation since we are transparent. I have devoted hundreds of volunteer hours for the RRDi in the hopes that some new members might turn our non profit into an active rosacea research and development but so far just haven't been able to generate the support we need to engage with anyone coming forward to volunteer and help. The other board members don't post. I haven't posted for sometime now and feel that since there really isn't anyone considering volunteering to actively support the mission of the RRDi, it may be time to simply shut it down. If you are an active member (there are only a few subscribers) could you post your thought on this? I am trying to be positive, but it looks rather bleak that rosacea sufferers want to unite and do anything except post on social media about rosacea. Actually engaging in rosacea research is left to the skin industry. Rosaceans just like rosacea social media sites and hang out there and do absolutely nothing about uniting as rosacea sufferers and doing anything but post in their favorite rosacea social media. Sure hope this thread generates some posts from anyone else, but I am losing hope. 
    • North Clin Istanb. 2024 Jan 31;11(1):27-37. doi: 10.14744/nci.2023.33410. eCollection 2024. ABSTRACT OBJECTIVE: Skincare is a part of rosacea treatment; patients benefit from complementary dermo-cosmetic care as well as medical treatments. Some skincare habits are known to trigger and exacerbate rosacea, but there are very few epidemiological studies on this matter. METHODS: A total of 200 people, including 100 patients with rosacea and 100 controls, were included in the study. We questioned the methods used by the participants in daily facial cleansing. Sun and heat exposure, makeup habits, the history of the use of topical steroids, and outdoor working status were noted. A dermoscopic examination, a non-invasive and valuable method to evaluate the presence and severity of Demodex, was performed. RESULTS: We evaluated 30% of our rosacea patients as erythematotelangiectatic rosacea, 13% as papulopustular rosacea, and 57% of our patients had mixed type, which could not be distinguished from one of these subtypes. In the case group, the proportion of people who used daily facial cleansers and daily soaps was lower than in the control group, while the proportion of those who cleaned their face with only water and those who used facial cleansers less frequently was higher (p<0.001). In the case group, while the rate of daily make-up and use of make-up products was lower (p=0.001, p<0.001, respectively), the rate of not wearing make-up was higher (p=0.001). The history of hot bath use was higher in the case group than in the control group (p=0.011). We found a significant relationship between the severity of plaque and dry appearance and the increase in Demodex density (p=0.007, p<0.001, respectively). CONCLUSION: We recommend that patients with rosacea clean their faces daily with soap or facial cleansers and not take a bath with very hot water. Patients should be evaluated for increased Demodex mites, especially if skin dryness is accompanied. PMID:38357320 | PMC:PMC10861432 | DOI:10.14744/nci.2023.33410 {url} = URL to article
    • J Imaging Inform Med. 2024 Jan 12. doi: 10.1007/s10278-023-00962-2. Online ahead of print. ABSTRACT The human body's largest organ is the skin which covers the entire body. The facial skin is one area of the body that needs careful handling. It can cause several facial skin diseases like acne, eczema, moles, melanoma, rosacea, and many other fungal infections. Diagnosing these diseases has been difficult due to challenges like the high cost of medical equipment and the lack of medical competence. However, various existing systems are utilized to detect the type of facial skin disease, but those approaches are time-consuming and inaccurate to detect the disease at early stages. To address various issues, a deep learning-based gate recurrent unit (GRU) has been developed. Non-linear diffusion is used to acquire and pre-process raw pictures, adaptive histogram equalization (AHE) and high boost filtering (HBF). The image noise is removed by using non-linear diffusion. The contrast of the image is maximized using AHE. The image's edges are sharpened by using HBF. After pre-processing, textural and colour features are extracted by applying a grey level run-length matrix (GLRM) and chromatic co-occurrence local binary pattern (CCoLBP). Then, appropriate features are selected using horse herd optimization (HOA). Finally, selected features are classified using GRU to identify the types of facial skin disease. The proposed model is investigated using the Kaggle database that consists of different face skin disease images such as rosacea, eczema, basal cell carcinoma, acnitic keratosis, and acne. Further, the acquired dataset is split into training and testing. Considering the investigation's findings, the proposed method yields 98.2% accuracy, 1.8% error, 97.1% precision, and 95.5% f1-score. In comparison to other current techniques, the proposed technique performs better. The created model is, therefore, the best choice for classifying the various facial skin conditions. PMID:38343253 | DOI:10.1007/s10278-023-00962-2 {url} = URL to article
    • Int Ophthalmol. 2024 Feb 12;44(1):60. doi: 10.1007/s10792-024-03002-2. ABSTRACT PURPOSE: To analyze higher-order aberrations (HOAs) and their visual impact in a pediatric blepharokeratoconjunctivitis (PBKC) cohort compared with healthy controls. METHODS: Prospective case-control study of pediatric patients (≤ 16 years old). Subjects underwent wavefront aberrometry analysis to compare HOAs and their impact on visual quality. RESULTS: A total of 150 eyes from 76 patients were included in the analysis. The PBKC group consisted of 50 eyes and the control group of 100 healthy eyes. Mean age was 10.39 ± 3.81 years for the PBKC group and 10.80 ± 3.61 years for the controls. Mean corrected-distance visual acuity (CDVA) was 0.24 ± 0.21 logMAR in the PBKC group and 0.07 ± 0.1 in the controls (P < 0.001). Mean astigmatism was 1.6 ± 1.98D in the PBKC group vs. 0.67 ± 0.76D in the control group (P = 0.01). Mean RMS of HOAs was 1.05 ± 1.7mm in the PBKC group and 0.41 ± 0.18mm in the controls (P < 0.001). The mean modulation transfer function (MTF) in the PBKC group was significantly lower (16.37 ± 16.32) than controls (30.3 ± 23.57) (P < 0.001). Corneal leukomas, stromal vascularization, peripheral nummular subepithelial scars, and pannus formation are associated with increased HOAs. CONCLUSIONS: There was a significant increase in total HOAs of eyes with PBKC compared to healthy controls. Corneal opacity, vascularization, and scarring are associated with increased HOAs. The PBKC eye aberration profile: coma, secondary astigmatism, quadrafoil, and pentafoil, were associated with decreased CDVA and visual quality (PSF and MTF). PMID:38345707 | DOI:10.1007/s10792-024-03002-2 {url} = URL to article
    • J Eur Acad Dermatol Venereol. 2024 Feb 10. doi: 10.1111/jdv.19852. Online ahead of print. NO ABSTRACT PMID:38339858 | DOI:10.1111/jdv.19852 {url} = URL to article
    • J Cosmet Dermatol. 2024 Feb 8. doi: 10.1111/jocd.16196. Online ahead of print. ABSTRACT BACKGROUND: The COVID-19 pandemic brought about a new normal, necessitating the use of personal protective equipment (PPE) like face shields, surgical masks, gloves, and goggles. However, prolonged mask-wearing introduced skin-related issues due to changes in the skin's microenvironment, including increased humidity and temperature, as well as pressure on the skin. These factors led to skin deformation, vascular issues, edema, and inflammation, resulting in discomfort and cosmetic concerns. Clinical reports quickly highlighted the consequences of long-term mask use, including increased cases of "maskne" (mask-related acne) or mask-wearing related disorders such as rosacea flare-ups, skin-barrier defects, itching, erythema, redness, hyperpigmentation, and lichenification. Some of these issues, like inflammation, oxidative stress, and poor wound healing, could be directly linked to acne-related disorders or skin hypoxia. AIM: To address these problems, researchers turned to rutin, a well-known flavonoid with antioxidant, vasoactive, and anti-inflammatory properties. However, rutin's poor water solubility presented a challenge for cosmetic formulations. To overcome this limitation, a highly water-soluble form of rutin was developed, making it suitable for use at higher concentrations. METHODS: In vitro and ex vivo tests were conducted, as well as an innovative clinical trial including volunteers wearing surgical masks for at least 2 h, to evaluate the biological activity of this soluble rutin on the main skin concerns associated with mask-wearing (inflammation, oxidative stress, skin repair, hyperpigmentation, and skin redness). RESULTS: The in vitro results showed that the active ingredient significantly reduced oxidative stress, improved wound healing, and reduced inflammation. In dark skin explants, the active ingredient significantly reduced melanin content, indicating its lightening activity. This effect was confirmed in the clinical study, where brown spots decreased significantly after 4 days of application. Moreover, measurements on volunteers demonstrated a decrease in skin redness and vascularization after the active ingredient application, indicating inflammation and erythema reduction. Volunteers reported improved skin comfort. CONCLUSION: In summary, the COVID-19 pandemic led to various skin issues associated with mask-wearing. A highly soluble form of rutin was developed, which effectively addressed these concerns by reducing inflammation, oxidative stress, and hyperpigmentation while promoting wound healing. This soluble rutin offers a promising solution for the rapid treatment of maskne-related disorders and other skin problems caused by prolonged mask use. PMID:38332551 | DOI:10.1111/jocd.16196 {url} = URL to article
    • Ann Dermatol. 2024 Feb;36(1):35-43. doi: 10.5021/ad.23.057. ABSTRACT BACKGROUND: More than half of acne patients have truncal acne on their chest, back, and shoulders. However, since most studies on acne have focused on the face, data on clinical characteristics and proper management for truncal acne are insufficient. OBJECTIVE: To establish a Korean Acne Rosacea Society (KARS) consensus for experts' perception and treatment patterns of truncal acne. METHODS: We conducted two rounds of the Dephi technique to gather expert opinion and reach a consensus on truncal acne. The first round comprised 48 questionnaires focusing on various aspects such as epidemiology, clinical features, diagnosis, treatment, prognosis and more, while second rounds consisted of 26 questionnaires. RESULTS: A total of 36 dermatologists (36/38 KARS members, 94.7%) completed this survey. In the first-round survey, consensus was reached on 20 out of the 48 questions (41.7%). In the second-round questionnaire, consensus was achieved on 9 of the 26 questions (34.6%). The most unresponsive lesion to truncal acne treatment was scars (atrophic/hypertrophic). The most commonly used treatments for each non-inflammatory and inflammatory truncal acne lesions were selected to use topical retinoids (78.1% of the responders) and oral antibiotics (93.8% of the responders). CONCLUSION: Our study has yielded valuable insights into the epidemiology, clinical manifestations, diagnosis, treatment, and quality of life of patients with truncal acne. We anticipate that this study will inspire further comprehensive research for individuals with truncal acne. PMID:38325432 | PMC:PMC10861305 | DOI:10.5021/ad.23.057 {url} = URL to article
    • Ann Dermatol. 2024 Feb;36(1):58-61. doi: 10.5021/ad.22.229. NO ABSTRACT PMID:38325436 | PMC:PMC10861309 | DOI:10.5021/ad.22.229 {url} = URL to article
    • Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x. ABSTRACT Clinically, rosacea occurs frequently in acne patients, which hints the existence of shared signals. However, the connection between the pathophysiology of rosacea and acne are not yet fully understood. This study aims to unveil molecular mechanism in the pathogenesis of rosacea and acne. We identified differentially expressed genes (DEGs) by limma and weighted gene co-expression network analysis and screened hub genes by constructing a protein-protein interaction network. The hub genes were verified in different datasets. Then, we performed a correlation analysis between the hub genes and the pathways. Finally, we predicted and verified transcription factors of hub genes, performed the immune cell infiltration analysis using CIBERSORT, and calculated the correlation between hub genes and immune cells. A total of 169 common DEGs were identified, which were mainly enriched in immune-related pathways. Finally, hub genes were identified as IL1B, PTPRC, CXCL8, MMP9, CCL4, CXCL10, CD163, CCR5, CXCR4, and TLR8. 9 transcription factors that regulated the expression of hub genes were identified. The infiltration of γδT cells was significantly increased in rosacea and acne lesions and positively linked with almost all hub genes. These identified hub genes and immune cells may play a crucial role in the development of rosacea and acne. PMID:38321132 | PMC:PMC10847114 | DOI:10.1038/s41598-024-53453-x {url} = URL to article
    • Skin Health Dis. 2023 Nov 22;4(1):e307. doi: 10.1002/ski2.307. eCollection 2024 Feb. ABSTRACT Skin diseases in Trinidad and Tobago, demonstating differences in Hospital vs Primary Care Dermatology Clinics, paediatric age groups and use of laboratory services. This figure illustrates, (a) combined percentage in range of skin diseases from all sites, n = 1309. Other diseases included CTD (connective tissue disease), papular urticaria, prurigo, rosacea and pityriasis rosea. (b) Paediatric dermatology conditions seen in one PCHF (primary care health facility) versus hospital clinics. (c) Comparison of waiting times, source of referrals and use of pathology in all PCHF versus hospital clinics. PMID:38312243 | PMC:PMC10831545 | DOI:10.1002/ski2.307 {url} = URL to article
    • Patient Prefer Adherence. 2024 Jan 31;18:249-253. doi: 10.2147/PPA.S444928. eCollection 2024. ABSTRACT OBJECTIVE: Artificial intelligence chatbot, particularly ChatGPT (Chat Generative Pre-trained Transformer), is capable of analyzing human input and generating human-like responses, which shows its potential application in healthcare. People with rosacea often have questions about alleviating symptoms and daily skin-care, which is suitable for ChatGPT to response. This study aims to assess the reliability and clinical applicability of ChatGPT 3.5 in responding to patients' common queries about rosacea and to evaluate the extent of ChatGPT's coverage in dermatology resources. METHODS: Based on a qualitative analysis of the literature on the queries from rosacea patients, we have extracted 20 questions of patients' greatest concerns, covering four main categories: treatment, triggers and diet, skincare, and special manifestations of rosacea. Each question was inputted into ChatGPT separately for three rounds of question-and-answer conversations. The generated answers will be evaluated by three experienced dermatologists with postgraduate degrees and over five years of clinical experience in dermatology, to assess their reliability and applicability for clinical practice. RESULTS: The analysis results indicate that the reviewers unanimously agreed that ChatGPT achieved a high reliability of 92.22% to 97.78% in responding to patients' common queries about rosacea. Additionally, almost all answers were applicable for supporting rosacea patient education, with a clinical applicability ranging from 98.61% to 100.00%. The consistency of the expert ratings was excellent (all significance levels were less than 0.05), with a consistency coefficient of 0.404 for content reliability and 0.456 for clinical practicality, indicating significant consistency in the results and a high level of agreement among the expert ratings. CONCLUSION: ChatGPT 3.5 exhibits excellent reliability and clinical applicability in responding to patients' common queries about rosacea. This artificial intelligence tool is applicable for supporting rosacea patient education. PMID:38313827 | PMC:PMC10838492 | DOI:10.2147/PPA.S444928 {url} = URL to article
  • Create New...

Important Information

Terms of Use